Arrowhead Pharmaceuticals Inc [ARWR] stock is trading at $22.14, down -2.60%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARWR shares have lost -0.72% over the last week, with a monthly amount glided 2.93%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] stock has seen the most recent analyst activity on June 05, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $31. Previously, BofA Securities started tracking the stock with Buy rating on December 04, 2023, and set its price target to $29. On September 19, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $33 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. SVB Securities downgraded its rating to a Market Perform but $40 remained the price target by the analyst firm on May 12, 2023. SMBC Nikko started tracking with a Outperform rating for this stock on April 26, 2023, and assigned it a price target of $80. In a note dated April 12, 2023, SVB Securities upgraded an Outperform rating on this stock and boosted its target price from $21 to $35.
Arrowhead Pharmaceuticals Inc [ARWR] stock has fluctuated between $17.05 and $39.83 over the past year. Currently, Wall Street analysts expect the stock to reach $27.74 within the next 12 months. Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] shares were valued at $22.14 at the most recent close of the market. An investor can expect a potential return of 25.29% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] reported sales of 3.55M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -2.82% with Operating Profit Margin at -169.27%, Pretax Profit Margin comes in at -172.48%, and Net Profit Margin reading is -168.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -2.07 and Total Capital is -0.58. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.67 points at the first support level, and at 21.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.80, and for the 2nd resistance point, it is at 23.45.
Ratios To Look Out For
For context, Arrowhead Pharmaceuticals Inc’s Current Ratio is 6.74. Also, the Quick Ratio is 6.74, while the Cash Ratio stands at 1.0. Considering the valuation of this stock, the price to sales ratio is 776.05, the price to book ratio is 14.85.
Transactions by insiders
Recent insider trading involved Oliver Tracie, Chief Commercial Officer, that happened on Jul 02 ’24 when 9394.0 shares were sold. Director, Vakiener Victoria completed a deal on May 02 ’24 to sell 1799.0 shares. Meanwhile, Chief Discovery/Trans Medicine Hamilton James C sold 6000.0 shares on Apr 01 ’24.
